NLG-207 is under clinical development by Ellipses Pharma and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NLG-207’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NLG-207 overview

NLG-207 (CRLX-101) is under development for the treatment of solid tumors including epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, small-cell lung cancer, rectal cancer and metastatic hormone refractory (Castration Resistant, Androgen-Independent) prostate cancer. The drug candidate is administered intravenously. It acts by targeting hypoxia inducible factor 1 (HIF-1) alpha and topoisomerase I. It comprises the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. The drug candidate is a poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate and it is developed based on cyclodextrin nanoparticle technology (CDP) (Cyclosert). It was also under development for the treatment of lymphoma, small cell lung cancer, non-small cell lung cancer, gastric Cancer, esophageal cancer, adenocarcinoma of the gastroesophageal Junction, metastatic triple negative breast cancer and metastatic renal cell carcinoma.

Ellipses Pharma overview

Ellipses Pharma is a drug development company focused on the advancement of innovative cancer treatments through the clinic. The company has developed a technology platform to access best oncology drug assets for further investigation, analysis and clinical development. Ellipses Pharma provides a permanent source of capital for the development of cancer assets and conducts multiple oncology clinical trials in parallel supported by Scientific Affairs Group. The company is building relationships with research institutions, charitable bodies, pharmaceutical, biotechnology companies, and outsourced development providers for delivering more treatment options in oncology. Ellipses Pharma is headquartered in London, England, the UK.

For a complete picture of NLG-207’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.